HopeStage
Back to all studies
CompletedNCT00962104

Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder

Medication studyAges 18+Multiple countriesADHD
The study in practice

Understand this study

Who was this study for?

This study was for people with ADHD. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Aichi and 23 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateAugust 2009
Recruitment status
Completed
Enrollment listed in the registry
391
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Japan, South Korea, Taiwan
Age range
Over 18 Years
Official registry ID
NCT00962104
Official title
Show the full official title

A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Aichi, Japan · Chiba, Japan · Fukushima, Japan

21 more locations
  • Hokkaido, Japan
  • Hyōgo, Japan
  • Kanagawa, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Nara, Japan
  • Osaka, Japan
  • Saitama, Japan
  • Tokyo, Japan
  • Bucheon-si, South Korea
  • Gwangjin-Gu, South Korea
  • Jeonju, South Korea
  • Seoul, South Korea
  • Sungnam-Si, South Korea
  • Yangsan, South Korea
  • Keelung, Taiwan
  • Neihu Taipei, Taiwan
  • Niao Sung Hsiang, Taiwan
  • Taichung, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine and Placebo.

Who was this study for?

This study was for people with ADHD. Listed age limits: from 18 years. Other eligibility criteria applied.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me